• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

AABB Bulletin Highlights Recommendations to Reduce the Risk of Transfusion-Related Acute Lung Injury (TRALI)

February 7, 2014

The AABB has released Association Bulletin #14-02 that summarizes the literature on the risks of transfusion-related acute lung injury (TRALI) and provides advice to meet Standard 5.4.1.2 which requires that “plasma and whole blood for allogeneic transfusion shall be from males, females who have not been pregnant, or females who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies.”

This new standard applies to whole blood designated for transfusion and all types of plasma.  In addition, to using male and never pregnant-female plasma, HLA antibody testing can be performed to possibly use plasma from female donors who have had one or more pregnancies or whose pregnancy history is unknown.  In addition, FDA-licensed pharmaceutical products such as OctaplasTM and KcentraTM are approved transfusion-therapy options. The Bulletin also highlights strategies for alleviating AB plasma shortages.  This new standard takes effect on April 1, 2014.

Reference

AABB Association Bulletin #14-02.   TRALI Risk Mitigation for Plasma and Whole Blood for Allogeneic Transfusion.  Jan 29, 2014.  Accessed online:  http://www.aabb.org/resources/publications/bulletins/Pages/default.aspx

 

Filed Under

  • Adverse Events (non-infectious)
  • News

Recommended

  • Characteristics of Transfusion Recipients in the United States

  • HLA-haploidentical Bone Marrow Transplantation May be Alternative Cure for Sickle Cell Patients

  • Recombinant von Willebrand Factor and Tranexamic Acid for Menstruating Women with von Willebrand Disease

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley